Product Information
OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 is a generic product labeled by Slate Run Pharmaceuticals LLC, priced at $0.7432 per EA under NDC 70436001404. Its NADAC has been published 29 times since Feb 4, 2026.
FDA first approved this application on May 14, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5
olmesartan medoxomil and amlodipine besylate and hydrochlorothiazideStrength
5; 12.5; 20 mg/1; mg/1; mg/1
Manufacturer
Slate Run Pharmaceuticals LLCNDC
70436001404
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMILApproval Type
Generic (ANDA)
FDA Application
ANDA210718FDA Approved
5/14/2025
TE Code
AB
On Market Since
5/15/2025
Pharmacological Classes
Price Statistics
The NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 has been published 29 times since Feb 4, 2026, and over the history we have for it it has declined 19.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7432 per EA |
|---|---|
| All-time high | $0.9312 (Mar 11, 2026) |
| All-time low | $0.7432 (Aug 19, 2026) |
| 52-week high | $0.9312 |
| 52-week low | $0.7432 |
| Median price | $0.8664 |
| Average price | $0.8636 |
| Largest weekly change | -10.7% (Jul 22, 2026) |
| Weeks tracked | 29 |
| Tracking since | Feb 4, 2026 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5?
The current National Average Drug Acquisition Cost (NADAC) for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5, manufactured by Slate Run Pharmaceuticals LLC, is $0.7432 per EA (NDC 70436001404), effective Aug 19, 2026.
How has the price of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 changed over time?
Over the history we have for it, the NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 has declined 19.3%. It has been tracked across 29 weekly CMS publications since Feb 4, 2026.
What are the highest and lowest recorded NADAC prices for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5?
Since Feb 4, 2026, the NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 has ranged from a low of $0.7432 (Aug 19, 2026) to a high of $0.9312 (Mar 11, 2026), with a median of $0.8664 per EA.
Are there cheaper alternatives to OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5?
No other NADAC-published product currently shares the active ingredient and strength of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5?
OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 (NDC 70436001404) is labeled by Slate Run Pharmaceuticals LLC, and CMS classifies it as a generic product.